Wildlife Health Market Report 2026

The wildlife health market size has grown rapidly in recent years. It will grow from $2.74 billion in 2025 to $3.02 billion in 2026 at a compound annual growth rate (CAGR) of 10%. The growth in the historic period can be attributed to rising incidences of wildlife diseases, increased establishment of zoos and wildlife sanctuaries, expansion of veterinary interventions for mammals and birds, development of specialized wildlife medicines, growing awareness about conservation and animal welfare.

The wildlife health market size is expected to see rapid growth in the next few years. It will grow to $4.53 billion in 2030 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to advancements in wildlife medicine and therapeutics, adoption of digital monitoring and tracking tools, increasing government support for wildlife health programs, growing ecotourism and conservation initiatives, integration of precision medicine in wildlife healthcare. Major trends in the forecast period include increased focus on wildlife disease surveillance, adoption of specialized veterinary medicines for wildlife, expansion of wildlife rescue and rehabilitation programs, growing demand for habitat health and conservation monitoring, use of injectable and oral therapies for diverse species.

The growth of the wildlife health market is also anticipated to be fueled by wildlife conservation measures and funding activities. Wildlife conservation involves a range of strategies aimed at preserving biodiversity, requiring substantial funding for habitat restoration, anti-poaching efforts, research initiatives, and community engagement. The wildlife health market plays a crucial role in supporting these efforts by providing essential services, diagnostics, and treatments that contribute to the overall well-being of wildlife populations. For instance, in September 2023, the United States Department of the Interior allocated over $40.6 million in grants to 10 states and the U.S. through the U.S. Fish and Wildlife Service, supporting habitat acquisition and protection. Therefore, wildlife conservation measures and funding activities are driving the growth of the wildlife health market.

Leading players operating in the wildlife health market are adopting advanced technologies to maintain their position in the market. These new technologies include sophisticated diagnostic tools, treatment approaches, and monitoring systems designed to enhance wildlife health management and disease prevention. For example, in February 2023, the US Department of Agriculture (USDA), a US-based federal agency, introduced new testing methods to track and detect COVID variants in wild and domestic animals. These tools support efforts to manage the spread of zoonotic diseases. The USDA Animal and Plant Health Inspection Service (APHIS) is implementing a $300 million provision under the American Rescue Plan Act to carry out monitoring and surveillance of animals susceptible to the COVID virus. Through this initiative, the Agricultural Research Service (ARS), in collaboration with APHIS, is conducting five research projects aimed at improving understanding of the virus and supporting APHIS’s objective of establishing an early warning system to help prevent or limit future zoonotic disease outbreaks or global pandemics.

In November 2025, Colossal Biosciences Inc., a US-based provider of genetic engineering, de-extinction, and conservation biology technologies, acquired Viagen Pets & Equine for an undisclosed amount. Through this acquisition, Colossal Biosciences sought to integrate advanced animal cloning and genetic technologies to support species conservation initiatives and expand its capabilities in preserving endangered wildlife and companion animal genetics. Viagen Pets & Equine is a US-based provider of animal cloning and reproductive biotechnology services, including pet and livestock cloning and related genomic technologies that support conservation and wildlife health research.

Major companies operating in the wildlife health market are Bayer AG, Novartis AG, Merck & Co Inc., Boehringer Ingelheim International GmbH, Elanco Animal Health Incorporated, IDEXX Laboratories Inc., Génia USA Inc., Orion Corporation, Virbac Group, Royal Canin, Ceva Santé Animale Group, Phibro Animal Health Corporation, Dechra Pharmaceuticals PLC, Huvepharma, Vétoquinol, Indian Immunologicals Limited, Norbrook Laboratories Limited, Heska Corporation, Biogenesis Bago, Animalcare Group plc, Pneu-Dart Inc., PetAg Inc.

North America was the largest region in the wildlife health market in 2025. The regions covered in the wildlife health market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the wildlife health market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the wildlife health market by raising costs for imported medicines, diagnostic equipment, and consumables, particularly impacting segments for mammals, birds, and reptiles in regions such as North America, Europe, and Asia-Pacific. Zoos, wildlife sanctuaries, and rescue centers are the most affected end-users. While tariffs increase operational expenses, they also encourage local production of wildlife medicines and equipment, promoting regional innovation and reducing reliance on imports.

The wildlife health market research report is one of a series of new reports that provides wildlife health market statistics, including wildlife health industry global market size, regional shares, competitors with a wildlife health market share, detailed wildlife health market segments, market trends and opportunities, and any further data you may need to thrive in the wildlife health industry. This wildlife health market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Wildlife health encompasses the physical, behavioral, and social well-being of an animal, considering its individual, population, and broader ecosystem levels, along with its capacity to adapt to change. It involves addressing the diverse stressors affecting wildlife.

The primary categories of wildlife health include mammals, birds, fish, reptiles, and amphibians. Mammals denote members of the vertebrate animal family whose offspring are nourished by the mother's milk from specific mammary glands. The products comprise medicine, equipment, and consumables, utilizing various routes of administration such as oral, injectable, and others. The end users encompass zoos, wildlife sanctuaries, wildlife rescue and rehabilitation centers, among others.

The wildlife health market consists of sales of immobilizing drugs, pharmaceutical drugs, and vaccines. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.